Neumora Therapeutics is trading at $0.47, down 5.62% in after-hours trading on November 6, 2026; no clear company-specific catalyst was identified.
- Neumora’s investor-relations page lists July 27 as its latest press release.
- A pre-market item described an earlier rise amid a possible market rebound, which does not explain the current decline.
- Broader-market attribution is unclear: supplied index figures were mixed while the stock moved down.